Media coverage about Ovid Therapeutc (NASDAQ:OVID) has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ovid Therapeutc earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.4998937484579 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Ovid Therapeutc (NASDAQ:OVID) traded up $1.10 during trading on Monday, reaching $8.84. The company had a trading volume of 75,406 shares, compared to its average volume of 73,986. Ovid Therapeutc has a 12-month low of $5.28 and a 12-month high of $15.93.
Ovid Therapeutc (NASDAQ:OVID) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). analysts predict that Ovid Therapeutc will post -4.61 EPS for the current year.
Separately, Zacks Investment Research raised Ovid Therapeutc from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $23.50.
ILLEGAL ACTIVITY WARNING: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/11/06/ovid-therapeutc-ovid-receives-coverage-optimism-score-of-0-08.html.
In other Ovid Therapeutc news, CEO Jeremy M. Levin purchased 15,334 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The stock was bought at an average price of $7.15 per share, with a total value of $109,638.10. Following the completion of the purchase, the chief executive officer now directly owns 4,601,529 shares of the company’s stock, valued at approximately $32,900,932.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Ovid Therapeutc Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
What are top analysts saying about Ovid Therapeutc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ovid Therapeutc and related companies.